Evidence map›Paper›PMID 32229492›Full record

ArticleAntimicrobial agents and chemotherapy2020

Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated

Maria-Ioanna Beredaki, Panagiota-Christina Georgiou, Maria Siopi, Lamprini Kanioura, David Andes, Maiken Cavling Arendrup, Johan W Mouton, Joseph Meletiadis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Maria-Ioanna BeredakiClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Panagiota-Christina GeorgiouClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Maria SiopiClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Lamprini KaniouraDepartment of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.
David AndesDepartment of Medicine and Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA.
Maiken Cavling ArendrupUnit of Mycology, Statens Serum Institut, Copenhagen, Denmark.ORCID 0000-0002-4747-0144
Johan W MoutonDepartment of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.
Joseph MeletiadisClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece jmeletiadis@med.uoa.gr.
National and Kapodistrian University of Athens · GRErasmus MC · NLStatens Serum Institut · DKUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CLSI and EUCAST susceptibility breakpoints for voriconazole and

Indexed as

Antifungal AgentsCandida albicansAnimalsCandidaMiceMicrobial Sensitivity TestsVoriconazoleAntifungal AgentsVoriconazoleantifungal susceptibility testingbreakpointsCandida albicansCLSIEUCASTPK/PDsusceptibility breakpointsvoriconazole

Identifiers

PMID32229492
PMCPMC7269500
OpenAlexW3013271739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.